Huntington National Bank Sells 20,919 Shares of Edwards Lifesciences Co. (NYSE:EW)

Huntington National Bank cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.6% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 221,147 shares of the medical research company’s stock after selling 20,919 shares during the quarter. Huntington National Bank’s holdings in Edwards Lifesciences were worth $14,594,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Crewe Advisors LLC purchased a new position in shares of Edwards Lifesciences in the 1st quarter worth $28,000. First Community Trust NA purchased a new position in Edwards Lifesciences in the second quarter worth about $29,000. Webster Bank N. A. bought a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at about $39,000. Peoples Bank KS purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $40,000. Finally, Versant Capital Management Inc lifted its stake in shares of Edwards Lifesciences by 206.3% in the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after purchasing an additional 326 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $66.15 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market cap of $39.02 billion, a price-to-earnings ratio of 9.55, a P/E/G ratio of 3.70 and a beta of 1.12. The firm has a fifty day moving average price of $67.42 and a 200 day moving average price of $76.44. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.59 earnings per share. As a group, sell-side analysts expect that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on EW shares. Baird R W downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. Bank of America downgraded shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and cut their price objective for the company from $105.00 to $75.00 in a research report on Thursday, July 25th. Piper Sandler decreased their target price on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Barclays cut their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Finally, Stifel Nicolaus decreased their price objective on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research note on Thursday, July 25th. Seventeen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $75.67.

Insider Activity at Edwards Lifesciences

In other news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 41,250 shares of company stock valued at $2,744,438 over the last 90 days. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.